Is Zegalogue Approved for Children with Type 1 Diabetes?
No, Zegalogue (dasiglucagon) is not approved for use in children, including those with type 1 diabetes. The FDA approved it in 2021 solely for adults and pediatric patients aged 6 years and older to treat severe hypoglycemia. Children under 6 are excluded due to insufficient safety and efficacy data in that group.[1][2]
What Clinical Data Exists for Kids?
In the pivotal trial for children, Zegalogue was tested in 42 patients aged 6 to less than 18 years with type 1 diabetes experiencing severe hypoglycemia. It reversed hypoglycemia faster than placebo (mean time to glucose ≥70 mg/dL: 12 minutes vs. 15 minutes). Common side effects included nausea (48%), vomiting (24%), and headache (21%), similar to adults. No new safety signals emerged, but the trial was small and short-term (single doses), limiting long-term insights.[1][3]
Why Not for Younger Children?
Dosing and safety haven't been established for kids under 6. The autoinjector delivers a fixed 0.6 mg dose, which may not suit smaller body sizes. Manufacturers advise against off-label use in this age group due to unknown pharmacokinetics.[1][2]
How Does It Compare to Alternatives Like Glucagon?
| Treatment | Ages Approved | Form | Key Differences for Kids with T1D |
|-----------|---------------|------|----------------------------------|
| Zegalogue | 6+ years | Ready-to-use autoinjector | Faster onset (10 min median); no mixing needed; higher nausea rates. |
| Baqsimi (glucagon nasal) | 4+ years | Nasal powder | Easier for caregivers; approved younger; similar efficacy but variable absorption if congested. |
| Gvoke (glucagon injection) | 2+ years | Prefilled syringe | Lowest age threshold; requires less training but still needs injection. |
| Traditional Glucagon Kit | All ages (off-label common) | Powder to reconstitute | Cheapest; harder to use in emergencies; widely available. |
For type 1 diabetes kids under 6, Gvoke or standard kits are standard; nasal options suit ages 4+.[2][4]
Common Parent Concerns on Safety
Parents report worries about vomiting triggering aspiration or GI distress delaying recovery. In trials, 10-20% of kids needed a second dose, like adults. It's contraindicated in pheochromocytoma or insulinoma. Monitor for hypersensitivity.[1][3] No post-marketing pediatric data shows unique risks yet.
Ongoing Studies or Patent Timeline
Phase 3 trials expanded pediatric data post-approval, but no updates for under-6s. Patents on Zegalogue expire around 2037-2041; generics unlikely soon.[5]
[1]: FDA Label for Zegalogue
[2]: Zealand Pharma Prescribing Info
[3]: NEJM Pediatric Trial (2021)
[4]: ADA Hypoglycemia Guidelines
[5]: DrugPatentWatch: Zegalogue Patents